Article
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
Current treatment options in oncology - 1 Jun 2024
Tecik Melisa, Adan Aysun
Abstract excerpt
OPINION STATEMENT: The internal tandem duplication (ITD) mutation of the FMS-like receptor tyrosine kinase 3 (FLT3-ITD) is the most common mutation observed in approximately 30% of acute myeloid leukemia (AML) patients. It represents poor prognosis due to continuous activation of downstream growth-promoting signaling pathways such as STAT5 and PI3K/AKT. Hence, FLT3 is considered an attractive druggable target;...
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- DNA Methylation
- Protein Kinase Inhibitors
- Antineoplastic Combined Chemotherapy Protocols
- Mutation
- Molecular Targeted Therapy
- Epigenesis, Genetic
- Epigenome